David Waltregny is currently professor of Urology and head of the Department of Urology at the University Hospital of Liège, Belgium. He holds membership in several professional and scientific organizations, amongst which the European and American Associations of Urology, and is a member of the scientific committee of the Belgian Association of Urology. After receiving his MD from the University of Liège, David Waltregny became a Senior Research Associate of the Belgian National Fund for Scientific Research, studying the mechanisms of tumor invasion and metastasis, and of hormone-independence in human prostate cancer, amongst other research projects. He then received a PhD in Experimental Biomedical Sciences from the University of Liège and completed a postdoctoral fellowship at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston. Professor Waltregny is the author and co-author of numerous publications in top-ranked international journals and serves as reviewer for several journals as well as for international grant applications. He is currently pursuing several research projects both at the clinical and fundamental levels, including studies aimed at identifying novel biomarkers of human prostate cancer for the development of targeted therapies, through the use of an original chemical/proteomic approach. He is also involved, together with Professor Jean de Leval, in the development of new surgical devices for the treatment of female and male stress urinary incontinence. He is the co-inventor of methods for treating smooth muscle disorders and for screening accessible biological markers in pathologic tissues, for which patents were issued.